Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bilateral CRSwNP.~* Prior treatment with systemic corticosteroids (SCS), and/or contraindicate to or intolerance to SCS, and/or with prior surgery to nasal polyps.~* Stable dose of intranasal corticosteroids for at least 4 weeks before screening.~* Ongoing symptoms for at least 4 weeks before screening：1)Nasal congestion/obstruction; 2)Othe symptom, e.g., loss of smell or rhinorrhea.~* Bilateral NPS of ≥5 with a minimum score of 2 in each nasal cavity at screening and at baseline.~* NCS score of 2 or 3 at screening and at baseline.~* Eosinophilic level meets the one of the following criteria: 1) serum eosinophil count ≥6.9% (without concomitant asthma) or ≥3.7% (with concomitant asthma) at screening; 2) absolute count of ≥55 per high power field or percentage of ≥27% in eosinophil level from nasal polyps biospy tissue.~* Contraception.~Exclusion Criteria:~* Not enough washingout period for previous therapy, e.g., less than 10 weeks or 5 half-lives (whichever is longer) for IL-4Rα antagonists, less than 8 weeks or 5 half-lives for biologic therapy/systemic immunosuppressant, less than 6 months for sinus surgery (including polypectomy).~* concurrent disease, e.g., ongoing rhinitis medicamentosa, acute sinusitis, nasal infection or upper respiratory infection, allergic fungal rhinosinusitis, malignancy, uncontrolled chronic disease such as cardivascular diseases, tuberculosis, diabetes etc.~* Allergic or intolerant to mometasone furoate spray or CM310/placebo.~* Significant liver or renal dysfunction.~* Other.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CM310 (Type: EXPERIMENTAL): CM310 300mg is given subcutaneously (SC) every two weeks for 16-week treatment
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is given subcutaneously (SC) every two weeks for 16-week treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).